Embecta Corp. Class Action Lawsuit - EMBC
Case Summary
Investors who suffered a loss and would like to learn more, click here to contact us.
The Embecta class action lawsuit seeks to represent purchasers or acquirers of Embecta Corp. (NASDAQ: EMBC) common stock between November 25, 2025 and May 4, 2026, inclusive (the “Class Period”). Captioned Apitz-Grossman v. Embecta Corp., No. 26-cv-07217 (D.N.J.), the Embecta class action lawsuit charges Embecta and certain of Embecta’s top executive officers with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Embecta class action lawsuit, please provide your information in the form on this page. You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at info@rgrdlaw.com. Lead plaintiff motions for the Embecta class action lawsuit must be filed with the court no later than August 17, 2026.
CASE ALLEGATIONS: Embecta is a medical device company that provides solutions to improve the health and well-being of people living with diabetes.
The Embecta class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) defendants created the false impression that Embecta was providing accurate and reliable fiscal guidance for second quarter and full year 2026; and (ii) Embecta knew or recklessly disregarded that segment weakness, especially in the United States pen needle market, was likely to disrupt Embecta’s original revenue guidance and second quarter 2026 results.
On May 5, 2026, Embecta announced its second quarter 2026 financial results, allegedly disclosing that Embecta missed its guidance for the second quarter and lowered its guidance for the 2026 fiscal year. Specifically, the Embecta class action lawsuit alleges that Embecta’s revenue declined over 14%, much higher than the guidance of flat to a decline of 2% and that Embecta was lowering estimates on U.S. performance, largely in part due to weakness in its pen needle sales. On this news, the price of Embecta stock decline nearly 58%, according to the complaint.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Embecta common stock during the Class Period to seek appointment as lead plaintiff in the Embecta class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Embecta class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Embecta class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Embecta class action lawsuit.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig.